Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details a specific transaction event where PDMRs acquired shares on April 11, 2016, at a price of 1472.57 pence per Ordinary Share through the GSK ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly lists the number of shares acquired by specific individuals under the personal contribution and matching elements of the ShareReward Plan.
Important Facts for Investors
- Transaction Date: Shares were acquired on April 11, 2016.
- Share Price: 1472.57 pence per Ordinary Share.
- Participants: 12 Directors and PDMRs, including Sir Andrew Witty and Dr P J T Vallance.
- Acquisition Volume: Most participants acquired 9 shares under the personal contribution element and 9 shares under the matching element; Dr P J T Vallance acquired 8 shares under each element.
- Plan Type: Acquisitions were made through the GSK ShareReward Plan.